Our Mission

Truly biomimetic

Utilizing a passionate and talented team, VoxCell has developed an extraordinary dual purpose 3D Bioprinter/Printer. Our unique 3D Bioprinter uses a state of the art laser with a process that crosslinks liquid polymers and bioinks with extreme precision, producing highly detailed 3D printed parts. This unique process occurs only at the focal point of the laser (the voxel, hence VoxCell), allowing for printing anywhere in the polymer, including within structures, unlike traditional 3D printers.

Our printer will produce highly detailed nanoscale tissue models with vasculature, mimicking human tissue, for in vitro drug testing and is aimed to dramatically reduce the time and resources spent in pre-clinical trials, which typically run approximately three years and $122M USD on average, and increase the successful translation between pre-clinical trial data and clinical trial results - currently less than 8%! The sooner drugs can be tested in truly biomimetic tissues, the better the development of the drug can be.

Our mission is simple: we want to change the world. We want to disrupt the drug development industry by getting life changing therapies into the market and the hands of people who need it most; faster and at a lower cost.

Meet the team

Dr. Karolina Valente

CEO

Andrew Garland,

CTO

Cameron Polglase,

Scientist

Zachary Nevin,

Applications Scientist

Christine Whiteside,

Operations

Dr. Leah Gajecki,

Chemist

Graeme Thompson,

Electrical Engineer

Byron Kontou,

Software Engineer

Megan Chisling,

Co-op

Jaedyn Foley,

Co-op

Josh Pord, 

Co-op

jj-ying-7JX0-bfiuxQ-unsplash_edited.jpg

advisors and partners

Dr. Alexandre Brolo,

Partner

Dr. Emma Davy,

Advisor

Martin Gurbin,

Advisor

jj-ying-7JX0-bfiuxQ-unsplash_edited.jpg

Dr. Nathan Lindquist,

Advisor

voxcell-logo@2x.png

© 2021 VoxCell BioInnovation Inc.

Victoria, BC, Canada

unnamed.png
Unknown.png

connect with us